EAFE Ishares MSCI ETF (EFA)
$61.67 0.71 (1.14%)
20:00 EDT EFA Stock Quote Delayed 30 Minutes
Previous Close $61.67
Market Cap 69.60B
PE Ratio -
Volume (Avg. Vol.) 26.10M
Day's Range 61.25 - 62.30
52-Week Range 45.72 - 70.42
Dividend & Yield 2.10 (3.40%)
EFA Stock Predictions, Articles, and EAFE Ishares MSCI ETF News
- From InvestorPlace
- From the Web
Those who are keeping their nerve during the Dow Jones correction can find strong sector ETFs to buy at incredible prices.
There are plenty of cheap ETFs for developed markets exposure, but these three stand out from the crowd. Here's what you need to know.
The iShares MSCI EAFE ETF (EFA) holds nearly 940 stocks based outside the U.S. Is the EFA the right way to get international exposure?
Analysts are divided on if they think this bull market can last, but agree its a bumpy ride. Smooth it over with these ETF plays
Has your financial advisor contacted you lately? Although markets have recovered from earlier losses, it's time to look over your portfolio again...
If you're looking for dividends, you'll want to check out these brand new international Vanguard funds: (VIHIX) and (VIAIX).
During the 10/2-10/07 bull market the media fawned over the critical importance of diversifying equity exposure across the globe. But not now
Stock market volatility is often portrayed by the mainstream media as an enemy. Here's how prudent investors use that volatility for gain...
Ibbotson Associates provides asset allocation guidelines that span the risk spectrum. Here's a moderate growth and income model for today
Today's blog post is dedicated to a wide-ranging overview of the global financial markets to gain a broad view on our next investment moves.
With the rebound in October, is it time to get back into international ETFs? The answer to that may lie in your personal risk tolerance.
When reviewing your overall investment portfolio check through your mutual fund holdings for costs and stock overlap. It can cost you money
The use of options to hedge a portfolio may come in handy, as 2015 gets off to a rocky start. Here are three to consider.
Both the media and financial advisers preach diversified portfolios, but if owning just one stock index like the S&P 500 safer? Find out here.
How long can this bull market go on? For an answer, investors can consult three indices with distinct trendlines.
Diversification won’t prevent market losses. But properly executed, it should limit risk and reduce your portfolio’s volatility.
Gainers: Corvus Pharmaceuticals (NASDAQ:CRVS) +108%.Annovis Bio (NYSEMKT:ANVS) +81%.Hepion Pharmaceuticals (NASDAQ:HEPA) +43%.Vivint Solar (NYSE:VSLR) +40%.Novavax (NASDAQ:NVAX) +35%.RealNetworks (NASDAQ:RNWK) +31%.Sunrun (NASDAQ:RUN) +28%.VBI Vaccines (NASDAQ:VBIV) +26%.CTI BioPharma (NASDAQ:CTIC) +20%.MOGU (NYSE:MOGU) +18%.Losers: Evolus (NASDAQ:EOLS) -31%.Broadway Financial (NASDAQ:BYFC) -29%.Sino-Global Shipping America (NASDAQ:SINO) -26%.Remark Holdings (NASDAQ:MARK) -23%.Top Ships (NASDAQ:TOPS) -20%.Urban One (NASDAQ:UONEK) -19%.Micro Focus International (NYSE:MFGP) -19%.Carver Bancorp (NASDAQ:CARV) -18%.Net Element (NASDAQ:NETE) -17%.CBAK Energy Technology (NASDAQ:CBAT) -16%.
Corvus Pharmaceuticals (NASDAQ:CRVS) +103% on launch immunotherapy study for COVID-19.Annovis Bio (NYSEMKT:ANVS) +85% on launch mid-stage study of lead drug in Alzheimer's and Parkinson's.Novavax (NASDAQ:NVAX) +35% after scoring $1.6B in funding from Operation Warp Speed.Hepion Pharmaceuticals (NASDAQ:HEPA) +23% on preclinical data supporting novel two-pronged approach to treating COVID-19 with CRV431.Vivint Solar (NYSE:VSLR) +21% on being acquired by Sunrun.Endo International plc (NASDAQ:ENDP) +19% as FDA approves Endo's Qwo for treatment of cellulite.AgEagle Aerial Systems (NYSEMKT:UAVS) +19%.BELLUS Health (NASDAQ:BLU) +15%.Otonomy (NASDAQ:OTIC) +14% on positive data on tinnitus candidate and Otividex.Future FinTech (NASDAQ:FTFT) +14% on Q1 results.ObsEva SA (NASDAQ:OBSV) +12%.Sunrun (NASDAQ:RUN) +11% on acquiring Vivint Solar.Livongo Health (NASDAQ:LVGO) +10% sees Q2 revenue as high as $87MVaxart (NASDAQ:VXRT) +9%.MYOS RENS Technology (NASDAQ:MYOS) +13% on publication of a study that evaluated the impact of Fortetropin on the rate of muscle protein synthesis in older adults.Northern Dynasty Minerals (NYSEMKT:NAK) +9% on Pebble partnership.Ayro (NASDAQ:AYRO) +7%.CTI BioPharma (NASDAQ:CTIC) +7%.Beasley Broadcast (NASDAQ:BBGI) +5%.